No7No7 Protect & Perfect Intense Advanced Serum & Laboratories Line Correcting Booster Serum Duo

BUY at Target

Discover No7's Protect and Perfect Intense Advanced Serum and Laboratories Line Correcting Booster Serum duo. A bundle that is clinically proven to reduce fine lines and wrinkles. Clinically proven to reduce the appearance of fine lines and wrinkles, Protect and Perfect Intense ADVANCED Serum is formulated with powerful age-defying ingredients that penetrate your skin?s surface 10 layers deep, targeting the look of damage you can?t see and visible signs you can. It re-energizes tired-looking skin and dramatically slows the appearance of the signs of aging* to keep skin looking younger for longer. Protect skin from environmental stressors and see results that get even better over time**. REAL RESULTS 84percent of women saw better age defying results when adding a No7 Protect and Perfect Serum to their regimen***? Instantly skin feels smoother***? After 2 weeks, skin appeared to look younger***? After 4 weeks, fine lines and wrinkles appeared visibly reduced***? 96percent showed a reduction in wrinkles and fine lines** *Based on clinical and consumer testing **Based on clinical testing ***Based on consumer testing on UK women The No7 Laboratories Line Correcting Booster Serum is clinically proven to reduce the appearance of stubborn lines and wrinkles by up to 5 years in 12 weeks*, this powerful, targeted booster serum features Matrixyl 3000+, No7's innovative anti-wrinkle peptide technology. Experience anti-aging skincare at its best. REAL RESULTS? In 1 week**, women saw a visible reduction in the appearance of lines and wrinkles on the forehead and around the eyes? By 2 weeks**, women saw visible improvements in the appearance of 6 targeted wrinkle areas (forehead, crow's feet, lips, between brows, under eyes and nasolabial folds) Among women who were considering injectables, after trialing the product for 2 months**:? 76percent said the serum gave them better results than they thought possible from skincare? 72percent said they were less likely to consider inje...